Strategies used to address barriers and facilitate mental health services use based on Andersen’s modified Behavioural model of Health Services Use.

<p>Strategies used to address barriers and facilitate mental health services use based on Andersen’s modified Behavioural model of Health Services Use.</p

Electronic decision support tools used at different stages of the intervention.

<p>Electronic decision support tools used at different stages of the intervention.</p

Baseline characteristics of ACS patients by prior use of four recommended medications.

<p>Baseline characteristics of ACS patients by prior use of four recommended medications.</p

Trends in risk of multiple in-hospital clinical outcomes with increasing number of prior medications used.

<p>HR: heart rate; MACEs: major adverse cardiovascular events; OR: odd ratio; SBP: systolic blood pressure; STEMI: ST-segment elevation myocardial infarction;</p

Multiple clinical outcomes (%) by prior medications use and multi-variable adjusted ORs (95%CI) among ACS patients.

<p>Multiple clinical outcomes (%) by prior medications use and multi-variable adjusted ORs (95%CI) among ACS patients.</p

Bleeding (%) by prior antiplatelet agents use and multi-variable adjusted ORs (95%CI) among ACS patients (%).

<p>Bleeding (%) by prior antiplatelet agents use and multi-variable adjusted ORs (95%CI) among ACS patients (%).</p

Polypills Meta-analysis ‘PRISMA’ Flow Diagram.

<p>Polypills Meta-analysis ‘PRISMA’ Flow Diagram.</p

ORs (95%CI) of prior medications use on in-hospital development of complications and MACEs among ACS patients after further adjusting for severity at presentation.

<p>ORs (95%CI) of prior medications use on in-hospital development of complications and MACEs among ACS patients after further adjusting for severity at presentation.</p

Actual vs Expected Reductions in Systolic Blood Pressure and LDL-cholesterol in Trials of ‘Polypills’.

*<p>rounded to nearest 10 mm Hg;</p>**<p>based on mean baseline SBP &amp; standard dose equivalence (from Law 2009) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052145#pone.0052145-Law1" target="_blank">[4]</a>;</p>∧<p>mean baseline LDL × percentage reduction in LDL cholesterol for the statin at that dose (from Law 2003) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0052145#pone.0052145-Law2" target="_blank">[5]</a></p>#<p>estimate: two drugs at half dose therefore an overestimate of likely effect;</p>##<p>estimate: two drugs at half dose therefore an underestimate of likely effect; 12.7 mmHg for two drugs at standard dose;</p>β<p>estimate: three drugs at standard dose; 15.2 mmHg for three drugs at half standard dose.</p

Forest Plots of Polypills versus Control for Change in Total Cholesterol and LDL-cholesterol.

<p>Forest Plots of Polypills versus Control for Change in Total Cholesterol and LDL-cholesterol.</p